UMIN ID: C000000429
Registered date:14/06/2006
oral CEF(Cyclophosphamide, Epirubicin, UFT) adjuvant chemotherapy for breast cancer with intra-patient dose escalation
Basic Information
| Recruitment status | Complete: follow-up complete |
|---|---|
| Health condition(s) or Problem(s) studied | Breast cancer |
| Date of first enrollment | 2006/07/01 |
| Target sample size | 26 |
| Countries of recruitment | Japan |
| Study type | Interventional |
| Intervention(s) | Adjuvant chemotherapy with oral cyclophosphamide and UFT with intra-patient dose escalation (Epirubicin) |
Outcome(s)
| Primary Outcome | Maximum tolerated dose (MTD) in oral CEF chemotherapy with intra-patient dose escalation |
|---|---|
| Secondary Outcome | Disease free survival time Adverse events graded by CTC |
Key inclusion & exclusion criteria
| Age minimum | 20years-old |
|---|---|
| Age maximum | 69years-old |
| Gender | Female |
| Include criteria | |
| Exclude criteria | Infection, Fever = or > 38C Serious comorbidity Interstitial pneumonitis/fibrosis Peripheral neuropathy/edema Positive HBsAg Prior use of Anthracycline Decision by primary physician |
Related Information
| Primary Sponsor | Outpatient Oncology Unit Kyoto University Hospital |
|---|---|
| Secondary Sponsor | |
| Source(s) of Monetary Support | None |
| Secondary ID(s) |
Contact
| public contact | |
| Name | Hiroshi Ishiguro, MD, PhD |
| Address | 54 Shogoinkawahara-cho, Sakyo-ku, Kyoto, Japan 606-8507 Japan |
| Telephone | 075-751-4770 |
| hkkishi@kuhp.kyoto-u.ac.jp | |
| Affiliation | Kyoto University Hospital Outpatient Oncology Unit |
| scientific contact | |
| Name | Hiroshi Ishiguro, MD, PhD |
| Address | 54 Shogoinkawahara-cho, Sakyo-ku, Kyoto, Japan 606-8507 Japan |
| Telephone | 075-751-4770 |
| hkkishi@kuhp.kyoto-u.ac.jp | |
| Affiliation | Kyoto University Hospital Outpatient Oncology Unit |